CASI Pharmaceuticals, Inc. (CASI) Year-over-year earnings per share growth for the last twelve months

CASI (CASI Pharmaceuticals, Inc) - company brandmark

The development of CASI Pharmaceuticals (CASI) relies on the introduction of oncology drugs to the Chinese market and regulatory approvals. This quarterly earnings per share growth chart visualizes these complexities, where the 0.00 mark serves as a key metric. Risks are linked to capital shortages and geopolitics, while business resilience is ensured by exclusive imports within the PRC's national subsidy system.

casipharmaceuticals.com (CASI) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 03/14/2026

CASI (CASI Pharmaceuticals): analytical breakdowns and indicator data

- market value and analyst target forecast:
Price Chart casipharmaceuticals.com|CASI - Average Forecast Price
- market capitalization details:
Market Value CASI|CASI - Total Enterprise Value
- book capitalization data:
Book Value per Share CASI Pharmaceuticals|CASI - Accounting Capitalization|Market Capitalization to Book Value Ratio casipharmaceuticals.com|CASI - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital CASI Pharmaceuticals|CASI - Long-Term Debt to Capital|Short-Term Debt to Equity casipharmaceuticals.com|CASI - Company Total Debt Obligations|Debts to Book Capitalization CASI|CASI - Long-Term Debt Volume|Company Current Liabilities CASI Pharmaceuticals|Quick Liquidity casipharmaceuticals.com
- earnings and valuation multiples indicators:
CASI - Profit After Tax|Projected Future Earnings CASI Pharmaceuticals|CASI - Company Value to Net Income|Forward P/E Multiple casipharmaceuticals.com|CASI - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CASI|CASI - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months CASI Pharmaceuticals|CASI - Net earnings per share for the last 12 months|Quarterly EPS earnings growth casipharmaceuticals.com|CASI - Earnings growth in current year|Earnings growth forecast for next year CASI Pharmaceuticals
Analysis of all company metrics:CASI Pharmaceuticals Inc. - CASI
Flagship merchandise of casipharmaceuticals.com

To filter out asset overvaluation risks, it is necessary to evaluate the dynamics of net earnings per share, calculated as the ratio of total income minus all expenses to the number of securities. By analyzing the quarterly earnings per share chart, an investor can determine how effectively the licensing of Western oncology drugs in China converts into real yield growth for CASI Pharmaceuticals (CASI).

Competitors of CASI Pharmaceuticals (CASI)

TG Therapeutics (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Inc (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Corp|Earnings per share growth in annualized terms for the last twelve months Syndax Corp SNDX|Quarterly EPS earnings growth KURA|adctherapeutics.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics Inc.)|VOR - Year-over-year net earnings per share growth for the last 12 months|Nkarta Corp - Quarterly EPS earnings growth|COEP - Quarterly EPS earnings growth|Actinium Pharmaceuticals (ATNM) - Year-over-year earnings per share growth for the last twelve months|ESLA - Year-over-year net earnings per share change for the last twelve months|MRKR (Marker Therapeutics Inc) - Quarterly EPS earnings growth|IN8bio Inc. (INAB) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ERNA (Eterna Therapeutics)|GTBP (GT Biopharma Corporation) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Aptose Biosciences APTO|BPTH (biopathholdings.com) - Year-over-year net earnings per share trend for the last twelve months|MEI Pharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months VINC (Vincerx Pharma, Inc.)